Immunocompetence may be important in the effectiveness of Mectizan® (ivermectin) in the treatment of human onchocerciasis
Immunocompetence may be important in the effectiveness of Mectizan® (ivermectin) in the treatment of human onchocerciasis
复制标题
DOI：
10.1016/s0001-706x(02)00117-1
复制
发表时间：
2002-10-01
期刊：
影响因子：
2.7
通讯作者：
Mackenzie, CD
中科院分区：
文献类型：
--
作者：
Ali, MMM;Mukhtar, MM;Mackenzie, CD
Mectizan（伊维菌素）已被证明是通过自我维持的社区治疗控制盘尾丝虫病的核心。最近在许多情况下出现了寄生虫学对这种治疗或耐药性选择无反应的可能性。Mectizan维持低水平皮肤微丝蚴和早期复发性瘙痒的能力降低的原因只能推测。在这里，我们报告我们自己的调查结果，以解决这个特殊的问题。出版社：Elsevier Science B.V.
Mectizan (Ivermectin) has been proved to be central to the control of onchoceriasis through self-sustainable community-based-treatment. The possibility of parasitological unresponsiveness to this treatment or selection for drug resistance has emerged recently in many occasions. The reason for the reduced ability of Mectizan to maintain low levels of dermal microfilariae and early recurrent pruritus can only be speculated upon. Here, we report our own findings to address this particular issue. Published by Elsevier Science B.V.